Efficacy and Safety of Desloratadine in Chronic Urticaria: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

ZHANG Xiaomin ¹ , GUO Jingbin ² , LI Qiang ² ,  ZHANG Tangde ¹

1. Department of Dematovereology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282,China2. Department of Cardiology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282,China;

Corresponding author：

ZHANG Tangde, Email: tdgz@medmail.com.cn

Keywords：

Desloratadine; Antihistamine medicine; Chronic urticaria; Systematic review

DOI：

10.7507/1672-2531.20090138

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives 　To evaluate the efficacy and safety of desloratadine in the patients with chronic urticaria(cu).
Methods 　We searched PubMed, Blackwell, BIOSIS Preview, The Cochrane Library, VIP and CNKI electronically from January 1, 2000 to April, 2008. Relevant journals and conference proceedings were also handsearched. Randomized controlled trials (RCTs) and quasi-RCTs comparing desloratadine with other medicines in the patients with CIU were considered eligible. The quality of the included trials was assessed by the Jadad scale, and meta-analysis was conducted using RevMan 5.0 software.
Results 　Nineteen trials involving 3,448 participants contributed to the meta-analysis. The results of the meta-analysis indicated that desloratadine showed similar effect on the improvement of signs and symptoms compared with loratadine RR 1.04 and 95%CI 0.99 to 1.09, mizolastine in RR 0.99 and 95%CI 0.92 to 1.07, cetirizine RR 1.05 and 95%CI 0.97 to 1.13 and terfenadine RR 1.10 and 95%CI 0.84 to 1.44. And desloratadine had similar safety to mizolastine RR 0.84 and 95%CI 0.45 to 1.58, ceririzine RR 0.67 and 95%CI 0.67 and 0.39 to 1.15 and terfenadine RR 0.44 and 95%CI 0.17 to 1.10. Desloratadine was safer than loratadine RR 0.74 and 95%CI 0.55 to 1.00.
Conclusions 　Desloratadine, the active metabolite of loratadine, is an oral, once-daily, non-sedating antihistamine that is effective in the treatment of CIU. Desloratadine provides rapid and sustained relief of CIU symptoms.

Citation： ZHANG Xiaomin,GUO Jingbin,LI Qiang,ZHANG Tangde. Efficacy and Safety of Desloratadine in Chronic Urticaria: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2009, 09(7): 796-801. doi: 10.7507/1672-2531.20090138 Copy

1.	Richard B, William D James, Harry L. ArnoldAndrew’s Diseases of the Skin: Clinical Dermatology. 8rd edition. W.B. Saunders Company, 1990.
2.	Greaves MW. Chronic urticaria. N Engl J Med, 1995, 332(26): 1767-1772.
3.	Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol, 1997, 133(8): 1003-1008.
4.	O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol, 1997, 136(2): 197-201.
5.	Ortonne JP, Grob JJ, Auquier P, et al. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol, 2007, 8(1): 37-42.
6.	DuBuske L. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol, 2007, 8(5): 271-283.
7.	Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy, 2004, 34(9): 1401-1407.
8.	Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol, 2001, 107(4): 751-762.
9.	Bousquet J, Bindslev-Jensen C, Canonica GW, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy, 2004, 59 Suppl 77: 4-16.
10.	Bonini S. Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction. Allergy, 2001, 56 Suppl 65: 5-6.
11.	Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
12.	周汛, 李惠, 王娟. 地洛他定与氯雷他定治疗荨麻疹临床对比观察. 重庆医科大学学报, 2003, 28(1): 78-79.
13.	顾军, 温海, 等. 地洛他宁治疗慢性特发性荨麻疹的疗效及安全性研究. 中国皮肤性病学杂志, 2002, 16(4): 227-229.
14.	兰长贵. 地洛他定治疗荨麻疹的临床疗效和安全性. 中国新药杂志, 2002, (08): 631-633.
15.	王克玉, 李春阳, 杨森, 等. 地洛他定治疗慢性特发性荨麻疹多中心双盲对照临床试验. 山东大学学报：医学版, 2005, 43(9): 842-844.
16.	钟华, 郝飞, 等. 地洛地定与氯雷他定治疗慢性特发性荨麻疹临床观察比较. 重庆医学, 2002, 31(11): 1106-1107.
17.	邹耘, 陈兴平. 地洛他定治疗慢性特发性荨麻疹的临床研究. 华中医学杂志, 2003, 27(2): 75-76.
18.	曾跃斌, 胡丽娜, 王恂, 等. 咪唑斯汀与地氯雷他定治疗慢性荨麻疹的随机单盲对照临床研究. 岭南皮肤性病科杂志. 2006, 13(2): 114-115.
19.	陈冰, 张华丽, 谢倩, 等. 地氯雷他定与咪唑斯汀治疗慢性荨麻疹的疗效和安全性比较. 岭南皮肤性病科杂志, 2004, 11(3): 240-242.
20.	郭义龙, 许敏鸿. 地氯雷他定治疗慢性荨麻疹疗效观察.岭南皮肤性病科杂志, 2004, 11(2): 130-132.
21.	郝飞, 彭振辉, 陈兴平, 等. 地洛他定和氯雷他定治疗慢性特发性荨麻疹多中心双盲对照临床试验. 中国皮肤性病学杂志, 2003, 17(4): 233-235.
22.	刘恩让, 张书岭, 刘妹丽. 地氯雷他定和盐酸西替利嗪治疗慢性荨麻疹临床对比观察. 实用诊断与治疗杂志, 2006, 20(4): 246-247.
23.	李芃, 姚鹏, 柯冰. 口服地氯雷他定治疗慢性荨麻疹疗效观察. 中华临床新医学, 2005, 5(2): 118-119.
24.	李占国, 陈燕辉, 田春. 地氯雷他定治疗慢性荨麻疹临床研究. 皮肤病与性病, 2006, 28(1): 11-12.
25.	梁敏奇. 地氯雷他定治疗慢性荨麻疹65例. 皮肤病与性病, 2006, 28(4): 34.
26.	邵明贤, 丁文玲. 地氯雷他定片治疗慢性荨麻疹疗效观察. 社区医学杂志, 2004, 2(2): 87.
27.	王刚, 李志武, 古新扬. 地氯雷他定治疗荨麻疹的疗效观察. 岭南皮肤性病科杂志, 2003, 10(3): 199-200.
28.	杨立英, 杨益峰. 咪唑斯汀与地洛他啶治疗慢性荨麻疹的成本-效果分析. 中国基层医药, 2007, 14(4): 578-579.
29.	张剑聪, 罗中权, 谭飞莉. 地氯雷他定与盐酸西替利嗪治疗慢性荨麻疹的成本-效果分析. 中国麻风皮肤病杂志, 2007, 23(6): 539.
30.	钟山, 陈永锋. 地氯雷他定治疗慢性荨麻疹疗效观察. 岭南皮肤性病科杂志, 2003, 10(3): 162-164.
31.	Grob JJ, Auquier P, Dreyfus I, et al. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol, 2008, 22(1): 87-93.
32.	Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol, 2004, 114(3): 619-625.
33.	Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol, 2003, 48(4): 535-541.
34.	Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol, 2001, 40(1): 72-76.

1. Richard B, William D James, Harry L. ArnoldAndrew’s Diseases of the Skin: Clinical Dermatology. 8rd edition. W.B. Saunders Company, 1990.
2. Greaves MW. Chronic urticaria. N Engl J Med, 1995, 332(26): 1767-1772.
3. Sabroe RA, Greaves MW. The pathogenesis of chronic idiopathic urticaria. Arch Dermatol, 1997, 133(8): 1003-1008.
4. O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol, 1997, 136(2): 197-201.
5. Ortonne JP, Grob JJ, Auquier P, et al. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol, 2007, 8(1): 37-42.
6. DuBuske L. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol, 2007, 8(5): 271-283.
7. Nettis E, Colanardi MC, Paradiso MT, et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy, 2004, 34(9): 1401-1407.
8. Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol, 2001, 107(4): 751-762.
9. Bousquet J, Bindslev-Jensen C, Canonica GW, et al. The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy, 2004, 59 Suppl 77: 4-16.
10. Bonini S. Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction. Allergy, 2001, 56 Suppl 65: 5-6.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
12. 周汛, 李惠, 王娟. 地洛他定与氯雷他定治疗荨麻疹临床对比观察. 重庆医科大学学报, 2003, 28(1): 78-79.
13. 顾军, 温海, 等. 地洛他宁治疗慢性特发性荨麻疹的疗效及安全性研究. 中国皮肤性病学杂志, 2002, 16(4): 227-229.
14. 兰长贵. 地洛他定治疗荨麻疹的临床疗效和安全性. 中国新药杂志, 2002, (08): 631-633.
15. 王克玉, 李春阳, 杨森, 等. 地洛他定治疗慢性特发性荨麻疹多中心双盲对照临床试验. 山东大学学报：医学版, 2005, 43(9): 842-844.
16. 钟华, 郝飞, 等. 地洛地定与氯雷他定治疗慢性特发性荨麻疹临床观察比较. 重庆医学, 2002, 31(11): 1106-1107.
17. 邹耘, 陈兴平. 地洛他定治疗慢性特发性荨麻疹的临床研究. 华中医学杂志, 2003, 27(2): 75-76.
18. 曾跃斌, 胡丽娜, 王恂, 等. 咪唑斯汀与地氯雷他定治疗慢性荨麻疹的随机单盲对照临床研究. 岭南皮肤性病科杂志. 2006, 13(2): 114-115.
19. 陈冰, 张华丽, 谢倩, 等. 地氯雷他定与咪唑斯汀治疗慢性荨麻疹的疗效和安全性比较. 岭南皮肤性病科杂志, 2004, 11(3): 240-242.
20. 郭义龙, 许敏鸿. 地氯雷他定治疗慢性荨麻疹疗效观察.岭南皮肤性病科杂志, 2004, 11(2): 130-132.
21. 郝飞, 彭振辉, 陈兴平, 等. 地洛他定和氯雷他定治疗慢性特发性荨麻疹多中心双盲对照临床试验. 中国皮肤性病学杂志, 2003, 17(4): 233-235.
22. 刘恩让, 张书岭, 刘妹丽. 地氯雷他定和盐酸西替利嗪治疗慢性荨麻疹临床对比观察. 实用诊断与治疗杂志, 2006, 20(4): 246-247.
23. 李芃, 姚鹏, 柯冰. 口服地氯雷他定治疗慢性荨麻疹疗效观察. 中华临床新医学, 2005, 5(2): 118-119.
24. 李占国, 陈燕辉, 田春. 地氯雷他定治疗慢性荨麻疹临床研究. 皮肤病与性病, 2006, 28(1): 11-12.
25. 梁敏奇. 地氯雷他定治疗慢性荨麻疹65例. 皮肤病与性病, 2006, 28(4): 34.
26. 邵明贤, 丁文玲. 地氯雷他定片治疗慢性荨麻疹疗效观察. 社区医学杂志, 2004, 2(2): 87.
27. 王刚, 李志武, 古新扬. 地氯雷他定治疗荨麻疹的疗效观察. 岭南皮肤性病科杂志, 2003, 10(3): 199-200.
28. 杨立英, 杨益峰. 咪唑斯汀与地洛他啶治疗慢性荨麻疹的成本-效果分析. 中国基层医药, 2007, 14(4): 578-579.
29. 张剑聪, 罗中权, 谭飞莉. 地氯雷他定与盐酸西替利嗪治疗慢性荨麻疹的成本-效果分析. 中国麻风皮肤病杂志, 2007, 23(6): 539.
30. 钟山, 陈永锋. 地氯雷他定治疗慢性荨麻疹疗效观察. 岭南皮肤性病科杂志, 2003, 10(3): 162-164.
31. Grob JJ, Auquier P, Dreyfus I, et al. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol, 2008, 22(1): 87-93.
32. Di Lorenzo G, Pacor ML, Mansueto P, et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. J Allergy Clin Immunol, 2004, 114(3): 619-625.
33. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol, 2003, 48(4): 535-541.
34. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol, 2001, 40(1): 72-76.

Chinese Journal of Evidence-Based Medicine

Efficacy and Safety of Desloratadine in Chronic Urticaria: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content